Skip to content
Subscriber Only

Teva Copaxone Appeal Decision Delayed by U.S. Supreme Court

The U.S. Supreme Court deferred a decision on whether to hear an appeal by Teva Pharmaceutical Industries Ltd. that aims to delay generic competition to its top-selling Copaxone multiple-sclerosis drug.

The justices took no action today on Teva’s bid for a hearing and are now scheduled to consider the case at their March 21 private conference, according to the court’s public docket.